Concord Biotech Limited vs Jubilant Pharmova Limited
Last updated: 24 October 2026
MoneyDock presents a detailed comparison between two prominent players in the Indian pharmaceutical sector: Concord Biotech Limited (CONCORDBIO.NS) and Jubilant Pharmova Limited (JUBLPHARMA.NS). Both companies operate within the broader healthcare and life sciences industry, offering a range of products and services. While Concord Biotech is known for its fermentation-based biopharmaceutical products, Jubilant Pharmova has a diversified presence in pharmaceuticals, contract research and development services, and proprietary novel drugs. Investors often compare such companies to assess their relative strengths in terms of market performance, financial stability, and future growth prospects within a dynamic and competitive industry.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Jubilant Pharmova Limited |
|---|---|---|
| Current Price | ₹1229.30 | ₹938.30 |
| 52-Week High | ₹1579.40 | ₹1087.10 |
| 52-Week Low | ₹1014.80 | ₹807.65 |
| 1-Year Return | -7.65% | -10.30% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When evaluating Concord Biotech and Jubilant Pharmova, several key aspects stand out from the provided data. In terms of valuation, both companies currently lack a Trailing P/E ratio, making a direct comparison on this widely used metric impossible with the given figures. Similarly, Market Cap data is not available for either company, which limits insights into their overall market size and scale. This absence suggests that investors would need to look for additional data sources to gain a complete picture of their valuations.
Regarding returns, both companies have experienced negative returns over the past year. Concord Biotech recorded a 1-Year Return of -7.65%, which, while negative, is slightly better than Jubilant Pharmova's -10.30%. This indicates that Concord Biotech has shown relatively more resilience in its share price performance over the last twelve months compared to its peer, despite both facing headwinds in the market. Neither stock has delivered positive returns for investors during this period.
For stability, we can look at the current price relative to their 52-week highs and lows. Concord Biotech's current price of ₹1229.30 is closer to its 52-week low of ₹1014.80 than its 52-week high of ₹1579.40. This suggests that the stock has experienced a significant correction from its peak. Jubilant Pharmova, with a current price of ₹938.30, is also positioned closer to its 52-week low of ₹807.65 than its 52-week high of ₹1087.10. Both stocks are trading well below their annual highs, reflecting a period of downward pressure. Concord Biotech's 52-week price range (₹1014.80 - ₹1579.40) is wider in absolute terms than Jubilant Pharmova's (₹807.65 - ₹1087.10), potentially indicating higher volatility for Concord Biotech, though a deeper analysis would require more data.
Without P/E and Market Cap data, a comprehensive valuation comparison remains challenging. However, based solely on the 1-Year Return, Concord Biotech has performed marginally better, incurring a smaller loss. Both companies show signs of recent price weakness, trading closer to their 52-week lows.
MoneyDock Verdict
Aggressive Investor: For aggressive investors, the lack of P/E and Market Cap data makes a high-conviction call difficult. However, given that both stocks are trading closer to their 52-week lows and have shown negative returns, an aggressive investor might see this as a potential entry point for a turnaround if they believe in the long-term prospects of either company. Concord Biotech's slightly better 1-Year Return might give it a slight edge for those looking for less severe recent losses, but the high uncertainty due to missing data necessitates thorough individual research.
Conservative Investor: Conservative investors would likely find both stocks less appealing at this juncture, primarily due to the negative 1-Year Returns and the absence of critical valuation metrics like Trailing P/E and Market Cap. The current prices being closer to 52-week lows suggest recent downward momentum. A conservative approach would involve waiting for more stable performance, positive returns, and the availability of comprehensive financial data before considering an investment. Both companies currently present a higher risk profile based on the available information.
Long-Term SIP Investor: For long-term SIP (Systematic Investment Plan) investors, the current dip, with prices closer to 52-week lows, could be seen as an opportunity for rupee-cost averaging, provided there is a strong conviction in the company's future growth and fundamentals beyond the provided data. Concord Biotech's lesser negative 1-Year Return (-7.65% vs -10.30%) might make it marginally more attractive if a choice must be made solely on recent performance. However, for a long-term SIP, consistent performance and strong underlying business health are paramount, and the missing data points are a significant gap that needs to be filled with further research before committing.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.